Evaluation of the Efficacy and Safety of Polatuzumab Vedotin Combined With Rituximab, Gemcitabine, and Oxaliplatin (Pola-R-GemOx) as Salvage Therapy for Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL) Patients Ineligible for Autologous Transplantation

NCT07001540 · clinicaltrials.gov ↗
PHASE2
Phase
RECRUITING
Status
130
Enrollment
OTHER
Sponsor class

Conditions

Interventions

Sponsor

Fudan University

Collaborators